We were delighted to speak with Dr Noa Krugliak Cleveland M.D. (University of Chicago, Chicago, IL, USA) around her talk on the RALEE study, investigating the impact of early initiation of vedolizumab in UC.
The abstract ‘EARLY VERSUS DELAYED INITIATION OF VEDOLIZUMAB IN ULCERATIVE COLITIS: TREATMENT RESPONSE IN THE REAL WORLD (RALEE)’ which was presented at the virtual 2022 Crohn’s & Colitis Congress, 20-22 January, 2022.
Questions
- What is known about the effect of timing of initiation of biologic therapies in ulcerative colitis? (0:10)
- What were the aims and design of the RALEE study? (0:58)
- What did the study tell us about patient characteristics and treatment patterns? (1:28)
- What can be done to ensure treatment patterns more closely match the guidelines? (2:13)
Disclosures: Noa Krugliak Cleveland discloses consulting for Takeda.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the virtual Crohn’s & Colitis Congress 2022.
